Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chenodeoxycholic Acid in IBS-C
NCT00912301Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2009
- Primary completion
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of chenodeoxycholic acid in irritable bowel syndrome (IBS) (3 arms), sponsored by Mayo Clinic. Primary endpoint: Colonic Geometric Center at 24 Hours. Started Apr 2009; status: completed.
02
Drugs
chenodeoxycholic acid
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT00912301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912301.